The authors report a case of primary rhabdomyosarcoma of the diaphragm, an extremely rare presentation with only 14 cases reported in the literature.
An 18-year-old male presented 2 spontaneous occurrences of pneumothorax. Computed tomography and magnetic resonance showed a tumoral mass on the right diaphragmatic surface, and after biopsy, the diagnosis was compatible with spindle cell rhabdomyosarcoma. Because the visceral pleura was invaded by the tumoral mass, a right pleuropneumonectomy was performed. The patient received adjuvant chemotherapy, and there was no evidence of disease 15 months after the operation.
Based on the Intergroup Rhabdomyosarcoma Study Group (IRSG) criteria, which consider the extent of the disease and its surgical resectability, rhabdomyosarcomas can be classified into 4 groups. In clinical group I, which was the classification of our patient, the tumor is localized and completely resectable, which implies a good prognosis. Rhabdomyosarcoma is a rare tumor, and a good outcome may result if it is completely resected. DESCRIPTORS: Rhabdomyosarcoma. Sarcoma. Diaphragm. Embryonal. Adolescent.
Rhabdomyosarcoma (RMS) is a malignant tumor arising in skeletal muscle, and it is the most common soft-tissue sarcoma in children and adolescents, accounting for 15% of soft-tissue sarcomas in the general population and 4% to 8% of all childhood malignancies 1 . There are 4 histologic subtypes of RMS: pleomorphic, alveolar, botryoid, and embryonal, the latter being the most frequently occurring soft-tissue sarcoma in childhood. The head and neck region and urogenital tract are most common sites of presentation [1] [2] [3] . The embyonal tumor is occasionally found in adults and the elderly. Primary rhabdomyosarcomas of the diaphragm are extremely rare tumors, with only 14 cases reported in the literature.
We present a case of diaphragmatic spindle cell embryonal rhabdomyosarcoma in a young male.
CASE REPORT
An 18-year-old male presented with dyspnea and ventilatory-dependent pain at the posterior region of the right hemithorax. He had experienced 2 spontaneous occurrences of pneumothorax, and during the second one (one year before admission to our department) a thoracotomy with biopsy and pneumothorax drainage were performed. Histologic examination was negative for malignancy. Physical examination showed reduced breath sounds at the right hemithorax.
CT scan (Fig. 1 ) demonstrated the presence of a 5-cm solid mass on the right pleural surface, extending to the right posterior mediastinum. He underwent videothoracoscopy with biopsy; microscopic exam revealed a spindle cell embryonal RMS, and immunohistochemical findings confirmed it.
Magnetic resonance (Fig. 2) showed an extensive lesion, with the largest diameter of 5 cm, at the base of the right hemithorax compressing the hepatic surface and extending to the right mediastinum.
Eleven months after surgery, a routine CT scan showed a probable recurrence of the tumor on the diaphragm. The patient underwent another thoracotomy revealing only a hematoma in the thoracic wall and intense local fibrosis. Resection of the hematoma and curettage of the thoracic wall were performed. Microscopic evaluation did not show recurrent disease.
At the follow-up evaluation 15 months after surgery, no evidence of disease was found.
DISCUSSION
Rhabdomyosarcoma (RMS) is the most frequently occurring soft tissue sarcoma in children and young adults and has been divided into 4 histologic subtypes: embryonal (58%), botryoid (subtype of embryonal, corresponding to 10 percent of RMSs), alveolar (14%), and pleomorphic (16%) 3, 4 . Rhabdomyosarcoma may occur at any site, but primary tumors are more commonly located in head and neck (42%), urogenital tract (34%), and extremities (11%) 3 . Alveolar tumors tend to occur primarily in trunk and extremities, whereas embryonal tumors are more often found in the head and neck or genitourinary and paratesticular sites 5 . Primary tumors of the diaphragm are uncommon entities, and diaphragmatic rhabdomyosarcoma is an extremely rare tumor 6 . Table 1 shows all 14 cases of primary RMSs of the diaphragm that have been reported since 1939.
In general, diaphragmatic tumors, either benign or malignant, do not express any symptom at the onset 10 . Our patient experienced 2 spontaneous occurrences of pneumothorax, which led us to start an investigation.
In contrast to the pediatric population, RMS in adults is comparatively rare, with the alveolar subtype predominating in adult patients 25 years of age or less, and the pleomorphic subtype predominating in adult patients over the age of 25 12 . Somatically acquired mutations underlie all forms of human cancer, but until recently, little was known about those associated with rhabdomyosarcoma. Cytogenetic and molecular genetic studies have identified both nu- During right thoracotomy, a diaphragmatic mass was identified, and multiple contiguous implants in the visceral and parietal pleura were noticed. Because of the extent of the lesion, a right pleuropneumonectomy and partial resection of diaphragmatic muscle with primary suture was performed. Histologic examination (Figs. 3a and 3b) revealed a poorly differentiated spindle cell sarcoma, compatible with spindle cell embryonal rhabdomyosarcoma, without nodal metastasis in the mediastinum.
The postoperative course was uneventful, and the patient was discharged from the hospital on the ninth postoperative day. Adjuvant chemotherapy with doxorubicin, ifosfamide, and dacarbazine was initiated. merical and structural abnormalities of tumor-cell chromosomes. Recurrent chromosomal translocations, including t(2;13)(q35;q14) and less commonly t(1;13)(p36;q14), have been identified in most cases of alveolar rhabdomyosarcoma [13] [14] [15] . The t(2;13) translocation results in fusion of part of the PAX3 gene to part of the FKHR gene, leading to formation of the PAX3-FKHR gene that encodes a chimeric protein.
In case of t(1;13) translocation, the PAX7-FKHR gene is formed [14] [15] [16] . The chimeric transcript may be detected by reverse transcription followed by polymerase chain reaction (PCR) 17 . Studies have suggested that clinical features, natural history of disease, and response to therapy differ in subgroups of patients according to the presence of t(2;13) or t(1;13) translocation or the absence of both translocations 15 . Some gene alterations other than PAX3/7-FKHR fusion might be markers of aggressiveness of RMSs. Alterations of the tumor suppressor p53 gene are the most frequent gene alterations in human cancer. These alterations are related to poor prognosis in several cancers including soft-tissue sarcomas in adults 18 . Cytogenetic and molecular abnormalities related to embryonal RMSs include hyperdiploidy 19 , trisomy of chromosomes 2, 13, and 18 20 , and loss of heterozygosity for polymorphic markers at 11p15.5 and 16q 20 . Other mutations or amplifications of tumorsuppressor genes, oncogenes, or tumorspecific fusion genes (e.g., p53, N-ras, K-ras and N-myc) are frequently observed and may be involved in the pathogenesis of rhabdomyosarcoma or may represent secondary events related to progression of the tumor 13, 20 . The Intergroup Rhabdomyosarcoma Study Group (IRSG) is the major worldwide protocol study group of rhabdomyosarcomas, and since 1972, has been conducting sequential prospective studies of these tumors. By 1998, these studies had included more than 3000 children, which comprised about three-fourths of all patients in North America 21 . According to the IRSG, rhabdomyosarcomas are divided into 4 surgical-histopathologic groups, based on the extent of disease, surgical decision, and extent of resection (Table 2) 1 . The international literature has been using this classification system for establishment of treatment and prognosis for patients with RMS 1,2 .
In all intergroup rhabdomyosarcoma studies (IRS), patients were randomized or assigned to therapy according to clinical group and received chemotherapy associated or not with radiotherapy (RT) after surgery. Therefore, prognostic factors and indications for RT and chemotherapy for different subtypes of RMS could be defined. In both IRS-I and IRS-II, survival at 5 years decreased from approximately 82% in patients with localized tumors that could be removed by surgery (clinical group I) to approximately 24% in patients with metastatic disease (clinical group IV). These results emphasize the crucial role of disease extent (i.e., clinical group) in predicting survival 1 
.
For patients with group I embryonal tumors, primary tumor location was strongly associated with outcome. Patients with tumors arising in genitourinary and paratesticular locations had a good prognosis 1, 5 , whereas patients with disease in the extremities had relatively poor survival 1 . No differences at outcome were observed when considering age, sex, study, or whether or not the patient received RT 5 . In IRS-I, patients with tumors larger than 5 cm in diameter had the poorest survival experience; tumor size was not related to survival in IRS-II 1 . Considering only histology and survival, patients with alveolar tumors fared the worst (5-year survival, 47% in IRS-I and 57% in IRS-II), whereas patients with botryoid or embryonal tumors had the best survival (95% and 92%, respectively) 1 . Estimated 10-year failure-free survival for patients with group I embryonal RMS was 92% in IRS-I and 81% in IRS-II 5 . The effect of RT on outcome was analyzed according to tumor histology for patients treated on IRS-I, II, and III, and no benefit was found for patients with group I embryonal RMS 5 . The patient in our study presented a mass on right diaphragm with contiguous implants in the parietal and visceral pleura. He underwent right pleuropneumonectomy with partial resection of the diaphragm. The decision was made to perform right lung resection because of the impairment of the visceral pleura. Using the IRSG criteria, this patient was classified as group I, since this group includes patients with complete tumoral resection without clinical and/or radiographic evidence of distant or nodal metastases. His histologic subtype (embryonal) and his clinical group are predictors of good prognosis. However, the size of tumor and its location were indicators of poor outcome.
The American Joint Committee for Cancer Staging (AJCC) system can also be used for staging patients with RMS and relies on histologic grade (G), tumor size (T), nodal status (N), and the presence or absence of distant metastases (M) 22 . According to this system, the patient would be classified as stage III. Nevertheless, the IRSG Group IV Distant metastases present at onset staging system was used, since this group studies only rhabdomyosarcoma and this classification system is specific for this kind of tumor. For unresectable local or regional tumors in less favorable sites, radiation therapy is recommended early in the course of treatment 21 . Radiation therapy was not performed because our patient did not fit in these criteria.
Neoadjuvant chemotherapy was not used because IRSG protocols still had not established the role of this therapeutic modality when our patient was treated; until IRS-III was completed, no protocol recommended neoadjuvant chemotherapy as the gold standard.
The classification of our patient into group I was based in the absence of compromised surgical margins in the resected mass; nevertheless, due to the size of the tumor, classification into group II cannot be totally excluded. However, this change in clinical group would not change the adjuvant treatment administered. Although IRS-IV recommends RT with 4100 cGy at week 9 (day 62) after surgery for group II patients, our patient could not receive this therapeutic regimen because a right deviation of the mediastinum had occurred. Because of the size of the tumor, we would have had to irradiate the entire right hemithorax from the diaphragmatic surface to the upper lobe of the lung. This irradiation would probably had affected the contralateral lung, the heart, and other deviated structures of the mediastinum in higher doses than these organs can tolerate.
We should also note that until IRS-IV was completed in 2000 (and which was ongoing at the time our patient was being treated), IRSG protocols did not show a benefit from using postoperative RT with patients with group I tumors. Nowadays, it is believed that radiation therapy may benefit group I patients who have a less favorable prognosis (e.g., alveolar histology) 23 . For patients with embryonal rhabdomyosarcoma in a site associated with a favorable outcome (i.e., the head and neck, but not the parameningeal area and the entire genitourinary tract except for the bladder and prostate) who have undergone complete or nearly complete resection (with only microscopic residual tumor), treatment with VA (vincristine and dactinomycin) is indicated according to IRSG protocols 21, 24 . However, patients with alveolar tumors require the addition of cyclophosphamide to the regimen. The cure rate among such low-risk patients is 90 to 95 percent, and about one-third of patients with newly diagnosed rhabdomyosarcoma belong to this low-risk group 13, 16 . Patients with all types of gross residual tumor, except orbital tumors, are considered to be at intermediate risk, with a cure rate of 70 to 80 percent, requiring more intensive chemotherapy that includes at least 3 drugs (vincristine, dactinomycin, and cyclophosphamide) 13, 16 . The fourth IRS compared VAC (vincristine, dactinomycin, and cyclophosphamide), VAI (vincristine, dactinomycin, and ifosfamide) and VIE (vincristine, ifosfamide, and etoposide) regimens and demonstrated no advantage in substituting cyclophosphamide for ifosfamide or dactinomycin for etoposide in the 3-drug chemotherapy regimen 25 . The fifth IRS is exploring use of these 3 drugs plus topotecan, the pioneer of the new class of anticancer agents, topoisomerase I inhibitors. The overall response to topotecan was 46% in patients with metastatic disease, and the response was better in alveolar tumors (65%) than in embryonal tumors (28%) 26 . Our patient received MAID (mesna, doxorubicin, ifosfamide, and dacarbazine) chemotherapy postoperatively, which is the first choice for sarcoma because it includes the two most effective drugs against this tumor (ifosfamide and doxorubicin) 27 . In spite of good responses of this combination, sometimes VAC may replace MAID regimen, as observed in IRSG protocols. Although less effective, the VAC regimen does not cause heart toxicity induced by doxorubicin.
Rhabdomyosarcoma is a malignant tumor that can arise at any site of the organism. Signs and symptoms depend on the anatomic site of the tumor, and prognosis varies according to tumor size, histology, localization, clinical group, and cytogenetic alterations. Better supportive care and systematic application of increasingly effective multimodal treatment have dramatically improved survival over this period, with 5-year survival rates rising from approximately 10 to 20 percent in 1970 to about 60 to 70 percent currently.
